Huge Gains for Biotron Share Price following Positive HIV Drug Trial Result

By ,

In just the past three trading days Biotron Limited [ASX:BIT] has rocketed up.

As at time of writing, it’s trading at $.093, a 489% increase from three trading days ago where it closed at $.019.

Biotron is a biotechnology research company working on a range of antiretroviral drugs.

Antiretroviral drugs fight viruses, and Biotron has recently had a positive drug trial result for its HIV medication.

Biotron working on other drugs as well

According to the company, the HIV drug is not the only one it’s working on:

The company is developing and commercialising a novel small molecule approach that has the potential to treat a number of serious viral diseases. The technology targets viroporin proteins, which are key to enabling the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus (RSV).

The HIV drug it’s developing is called BIT225, which based on the Phase 2 clinical trial is demonstrating, ‘significant immunological benefits’.

The drug does this by rooting out the virus from cellular ‘reservoirs’.

In other words, the virus builds up in cells and current drugs are unable to remove this build up.

BIT225 is being hailed as ‘…a major step to the ultimate goal of curing HIV-1 infection.’

The Key to Spotting Breakout Biotech Stocks. Download your free report now.

Biotron Director: ‘No one has done this before

The company’s Managing Director, Dr Michelle Miller, says that:

No one has done this before, and there were no guidelines to follow. We have had to use a range of techniques to show that BIT225 has done what we expected it to do.’

This can only be big news for Biotron, with the share currently experiencing a 259% one year return.

Small-cap/micro-cap biotech stocks are notoriously difficult to gauge as so much rides on the outcomes of clinical trials.

We will be watching Biotron as it presents its findings to the scientific community over the coming months.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

PS: How to get in on these high-risk tech plays with massive potential. Find out here.

About Ryan Clarkson-Ledward

Ryan Clarkson-Ledward is an Editor at Money Morning.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan is also the Editor…

Biotron Share Price Shoots 26% Higher on Preliminary COVID-19 Results

The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021…

Three Stocks to Watch during the Coronavirus Rollercoaster

Market volatility is continuing to rise amidst the ongoing global pandemic. Worst yet, it is difficult to pinpoint when this is likely to end. Markets are up one day and crashing down the next. It is a telling sign when investors begin to look for safety among some of Australia’s most speculative small-caps…

A Look at the Orthocell Share Price: Can It Keep Going Up? 

Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May .Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward. 

Biotron Share Price Up, Letter to Shareholders Includes Useful Information

Early this morning, the share price of Biotron Limited [ASX:BIT] managed to spike up 7.69%, trading at 14 cents per share. In a letter to the shareholders, the company disclosed a couple of useful pieces of information.

Biotron Share Price Volatile as Investors Digest Latest Release

It’s been a rollercoaster ride for the Biotron Limited [ASX:BIT] share price, with the stock up 14.82% today, trading at $.155 at time of writing. Reasons for the current volatility are hard to pin down, but profit-taking and new data released by the company could be factors. The Biotron share price is down from a high of … Read More

Biotron Share Price Up as it Responds to ASX Query

The share price of Biotron is up 9.5% and trading at $0.115, at time of writing. It has been an exciting time for Biotron shareholders who, last month, could have sold their shares for a whopping $0.445.